Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Shares of clinical-stage biopharmaceutical company BioXcel Therapeutics, Inc. (BTAI) are down 13 percent on Wednesday's trading as the company announced the pricing of an underwritten public offering of 3.15 million shares at $31.70 per share.


RTTNews | Jun 23, 2021 03:12PM EDT

15:11 Wednesday, June 23, 2021 (RTTNews.com) - Shares of clinical-stage biopharmaceutical company BioXcel Therapeutics, Inc. (BTAI) are down 13 percent on Wednesday's trading as the company announced the pricing of an underwritten public offering of 3.15 million shares at $31.70 per share.

The company expects gross proceeds from the underwritten public offering to be around $100 million and said that it will not receive any proceeds from any sale of shares in this offering by BioXcel LLC. The offering is expected to close on or about June 25.

Currently trading at $32.03, the stock has traded between $28.00 and $71.50 during the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3204493/bioxcel-therapeutics-tanks-13-on-new-share-public-offering.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC